Creative Medical Technology Holdings, Inc. CELZ

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001187953

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $7.8M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, thin data, degenerate inputs not computable: short runway, distress
Inputs computable	6 of 14
Graded from	filings received through Apr 24, 2026 180 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026
Last close	$0.78 2026-10-20; market equity $5.1M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 20, 2026

We are a commercial stage biotechnology company dedicated to the advancement regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following: Our subsidiary, Creative Medical Technologies, Inc. ("CMT"), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction ("ED"), which it acquired in February 2016.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 85.4						
Gross profitability	0.05%	32.3%		94.3	371	2025-12-31
Return on invested capital	not computable	9.3%				
required facts have no common fiscal period end						
Accruals ratio	(1.9%)	(6.6%)		76.4	812	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts				
annual revenue must exceed $100,000						
Solvency, sleeve percentile 22.0						
Twelve-month failure probability	not computable	0.06%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(1.08)	(0.30)		41.5	757	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
interest expense must exceed $100,000						
Current ratio	25.97x	2.96x		2.5	840	2025-12-31
Growth and financing, sleeve percentile 81.8						
Revenue growth, three-year compound	not computable	10.1%				
current value must be positive and the base must exceed $100,000						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 0						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(25.9%)	2.1%		89.3	705	2025-12-31
Net share issuance, one year	43.0%	2.4%		74.2	633	2026-03-20

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 43.0%
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-10-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(66.1%)	8.0%	8
Distance from 52-week high	(86.5%)	(29.7%)	6
EBIT to enterprise value	(109.4%)	(1.5%)	6
Free cash flow yield	not computable	(1.0%)	
Book value to price	1.74	0.28	94
Sales to price	0.00	0.30	3
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(1.29)	(0.13)	8

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	75 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	$189,907

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$3,806	2025-12-31	2026-03-20	10-K	26-001517
2	assets	us-gaap:Assets	$7.8M	2025-12-31	2026-03-20	10-K	26-001517
3	net income	us-gaap:NetIncomeLoss	-$6.0M	2025-12-31	2026-03-20	10-K	26-001517
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.9M	2025-12-31	2026-03-20	10-K	26-001517
5	assets	us-gaap:Assets	$6.7M	2024-12-31	2026-03-20	10-K	26-001517
6	revenue	us-gaap:Revenues	$6,000	2025-12-31	2026-03-20	10-K	26-001517
7	current assets	us-gaap:AssetsCurrent	$7.4M	2025-12-31	2026-03-20	10-K	26-001517
8	current liabilities	us-gaap:LiabilitiesCurrent	$284,880	2025-12-31	2026-03-20	10-K	26-001517
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$70.6M	2025-12-31	2026-03-20	10-K	26-001517
10	operating income	us-gaap:OperatingIncomeLoss	-$6.1M	2025-12-31	2026-03-20	10-K	26-001517
11	book equity	us-gaap:StockholdersEquity	$7.5M	2025-12-31	2026-03-20	10-K	26-001517
12	liabilities	us-gaap:Liabilities	$284,880	2025-12-31	2026-03-20	10-K	26-001517
13	operating income	us-gaap:OperatingIncomeLoss	-$10.2M	2022-12-31	2024-03-22	10-K	24-001431
14	interest expense	us-gaap:InterestExpense	$0	2022-12-31	2023-03-31	10-K	23-002123
15	revenue	us-gaap:Revenues	$11,000	2024-12-31	2026-03-20	10-K	26-001517
16	revenue	us-gaap:Revenues	$9,000	2023-12-31	2025-03-14	10-K	25-001736
17	revenue	us-gaap:Revenues	$88,600	2022-12-31	2024-03-22	10-K	24-001431
18	assets	us-gaap:Assets	$10.7M	2023-12-31	2025-03-14	10-K	25-001736
19	assets	us-gaap:Assets	$19.2M	2022-12-31	2024-03-22	10-K	24-001431
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	3,696,668	2026-03-20	2026-04-24	10-K/A	26-002534
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,585,897	2025-04-15	2025-04-25	10-K/A	25-002984

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.